# A Study of the Effects of AB-205 in Patients With Lymphoma Undergoing Autologous Hematopoietic Cell Transplantation

> **NCT05181540** · PHASE3 · TERMINATED · sponsor: **Angiocrine Bioscience** · enrollment: 130 (actual)

## Conditions studied

- Hodgkin Lymphoma
- Non Hodgkin Lymphoma

## Interventions

- **BIOLOGICAL:** AB-205
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT05181540
- **Lead sponsor:** Angiocrine Bioscience
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-02-21
- **Primary completion:** 2023-12-29
- **Final completion:** 2025-01-31
- **Target enrollment:** 130 (ACTUAL)
- **Why stopped:** Interim analysis showed lack of efficacy
- **Last updated:** 2025-02-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05181540

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05181540, "A Study of the Effects of AB-205 in Patients With Lymphoma Undergoing Autologous Hematopoietic Cell Transplantation". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05181540. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*